On January 28, C-Path’s Translational Therapeutics Accelerator (TRxA) unveiled its 2025 global Request for Proposals (RFP). This year, TRxA has merged its efforts to support both biologics and small molecule therapeutics under a single, unified RFP.
Our combined initiative, designed to advance novel therapeutics through the challenging drug development process, will feature a comprehensive approach to funding and support. Whether your research focuses on cutting-edge protein-based therapeutics (PBTs), gene-based therapies, or early-stage small molecule drug development, this RFP aims to provide the crucial resources needed to bridge the gap from lab discoveries to potential clinical applications.
In this webinar, we covered:
- An overview of the new combined RFP, encompassing both large and small molecules;
- Detailed information about the types of projects eligible for funding, including those for novel protein-based therapeutics, gene-based therapies and small molecule lead optimization, through IND-enabling studies;
- Eligibility criteria and application procedures for this funding opportunity;
- Insights into how TRxA supports projects through the drug development valley of death to enhance licensing prospects.
The session included a live Q&A to address questions and provided further clarity on how to make the most of this unique opportunity. Don’t miss this chance to learn how TRxA’s 2025 RFP can support your innovative research and propel it towards impactful therapeutic solutions.
